换用英夫利昔单抗生物类似药后出现血清病样疾病。 - Suppr

Suppr

超能文献

Serum sickness-like disease after switching to biosimilar infliximab.

作者信息

Scherlinger Marc, Schaeverbeke Thierry, Truchetet Marie-Elise

机构信息

Service de Rhumatologie, Centre Hospitalier Universitaire de Bordeaux.

Université de Bordeaux.

出版信息

Rheumatology (Oxford). 2017 Nov 1;56(11):2032-2034. doi: 10.1093/rheumatology/kex268.

DOI:10.1093/rheumatology/kex268

PMID:28977481

Abstract

摘要

相似文献

Serum sickness-like disease after switching to biosimilar infliximab.

Rheumatology (Oxford). 2017 Nov 1;56(11):2032-2034. doi: 10.1093/rheumatology/kex268.

Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):171-172. Epub 2018 Jan 15.

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.

Ann Rheum Dis. 2018 Feb;77(2):234-240. doi: 10.1136/annrheumdis-2017-211741. Epub 2017 Oct 17.

Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar.

Neurology. 2020 Jun 2;94(22):991-993. doi: 10.1212/WNL.0000000000009526. Epub 2020 May 11.

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

Int J Rheum Dis. 2019 May;22(5):869-873. doi: 10.1111/1756-185X.13512. Epub 2019 Feb 14.

SB2: An Infliximab Biosimilar.

BioDrugs. 2017 Oct;31(5):461-464. doi: 10.1007/s40259-017-0240-7.

Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.

Dermatol Ther. 2019 May;32(3):e12846. doi: 10.1111/dth.12846. Epub 2019 Feb 22.

A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate.

Mod Rheumatol. 2019 Nov;29(6):919-927. doi: 10.1080/14397595.2018.1533063. Epub 2018 Dec 20.

Inflamm Bowel Dis. 2020 Jul 17;26(8):e83-e84. doi: 10.1093/ibd/izaa128.

Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):88-94. doi: 10.1002/acr.23771.

引用本文的文献

Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System.

BioDrugs. 2023 May;37(3):397-407. doi: 10.1007/s40259-023-00584-8. Epub 2023 Mar 6.

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.

Pharmaceutics. 2022 Aug 24;14(9):1766. doi: 10.3390/pharmaceutics14091766.

The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Front Pharmacol. 2021 May 28;12:680043. doi: 10.3389/fphar.2021.680043. eCollection 2021.

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.

Aliment Pharmacol Ther. 2019 Jan;49(1):31-40. doi: 10.1111/apt.14997. Epub 2018 Nov 8.

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.

Drugs. 2018 Mar;78(4):463-478. doi: 10.1007/s40265-018-0881-y.

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.

Rheumatology (Oxford). 2018 Nov 1;57(11):1896-1907. doi: 10.1093/rheumatology/kex434.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验